Source comparison
BPC-157 Studied MS Research: Dosing and Safety Data Comparison
EAE Rats (2019) 10 µg/kg daily Intraperitoneal injection 40–60% vs controls Preserved myelin structure, reduced inflammatory infiltrate No adverse effects reported at therapeutic doses EAE Mice (2020) Subcutaneous injection 35–50% vs controls Increased M2 micr
This comparison does not assign a generated winner or score.
- EAE Rats (2019)
- 10 µg/kg daily
- Intraperitoneal injection
- 40–60% vs controls
- Preserved myelin structure, reduced inflammatory infiltrate
- No adverse effects reported at therapeutic doses
- EAE Mice (2020)
- Subcutaneous injection
- 35–50% vs controls
- Increased M2 microglia, reduced BBB permeability
- Well-tolerated across 28-day treatment period
- In Vitro OPC Culture
- 1–10 µg/mL
- Direct media exposure
- N/A (cell survival assay)
- 40–50% reduction in cytokine-induced apoptosis
- No cytotoxicity observed at concentrations up to 100 µg/mL
- EAE Rats (2017)
- 45–55% vs controls
- Normalized iNOS expression, reduced oxidative stress markers
- No hepatotoxicity or nephrotoxicity in repeated dosing studies